ACRS News and Press, Aclaris Therapeutics Inc. From 09/18/23

– Preliminary Data Support Progression to Phase 2a Proof of Concept Trials in T cell-mediated Autoimmune Diseases – WAYNE, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on dev...

2023-09-14 19:03:25 ET Aclaris Therapeutics (NASDAQ: ACRS) had a fine Thursday, at least as far as its stock was concerned. The biotech's shares enjoyed a nearly 6% lift in price, thanks largely to a generous price-target boost from an analyst. That professional is Stifel Fina...

2023-09-14 10:00:06 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...

2023-08-29 11:51:18 ET More on Aclaris Therapeutics Aclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must Watch Aclaris stock falls ~35% as zunsemetinib fails mid-stage study in skin disorder Goldman Sachs initiates Aclaris at Buy citing potential in lead asset...

2023-08-07 07:17:26 ET Aclaris Therapeutics press release ( NASDAQ: ACRS ): Q2 GAAP EPS of -$0.42 beats by $0.03 . Revenue of $1.87M (+22.2% Y/Y) misses by $0.03M . For further details see: Aclaris Therapeutics GAAP EPS of -$0.42 beats by $0.03, revenue o...

- Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced; Data Expected in Q4 2023 - WAYNE, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing n...

2023-07-11 19:31:22 ET Summary Aclaris Therapeutics, Inc. results from a phase 2b study using zunsemetinib for the treatment of patients with rheumatoid arthritis are expected to be released by Q4 of 2023. The global rheumatoid arthritis market is expected to reach $33.3 billion b...

2023-06-13 18:30:31 ET Biotech investors like it when one of their companies reports gains in a developmental program, and that was the dynamic behind Tuesday's rise in the share price of Aclaris Therapeutics (NASDAQ: ACRS) . The company's stock gained 2.5% in value on the day, a fi...

- Topline Data Anticipated in Q4 2023 WAYNE, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of enrol...

2023-06-02 17:22:22 ET Gainers: Lyra Therapeutics ( LYRA ) +13% . Hibbett ( HIBB ) +4% . Infinera Corporation ( INFN ) +3% . Gladstone Commercial  ( GOOD ) +3% . Aclaris Therapeutics ( ACRS ) +2% . Losers: Trupanion ...